Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The Community for Open Antimicrobial Drug Discovery aims to tap into the potential of the millions of compounds distributed around laboratories globally to be a source of new antibiotic leads by offering free screening for antimicrobial properties, with no strings attached.
Induced pluripotent stem cell-derived 'disease-in-a-dish' models have propelled neurological drugs from Bristol-Myers Squibb, GlaxoSmithKline and Roche into clinical trials.
Amyloid-targeted antibodies seem to have a small clinical benefit in patients with mild Alzheimer disease, but issues with the design and interpretation of the trials curb enthusiasm.
Gloria Maldonado, Executive Director of Pfizer's Center of Excellence in Precision Medicine in Chile, discusses pharma's R&D expansion into Latin America.
This article analyses the first three years of the US Food and Drug Administration's breakthrough therapy designation programme, which was established to expedite development and approval of products to treat serious diseases.
Small-molecule drugs have several advantages that are complementary to, and possibly synergistic with, biologic approaches for anticancer immunotherapy. This Review provides an overview of immunological pathways that can best be targeted with small molecules and discusses how these approaches fit into the armamentarium of immunotherapeutic strategies for cancer.
Nitric oxide (NO) is now established as a pivotal signalling molecule in the regulation of the cardiovascular system, and it has an important role in protection against cardiovascular disease. Here, Lundberget al. discuss the limitations of existing NO-targeting agents and assess emerging novel approaches to therapeutically modulate NO bioavailability.
Oncolytic viruses can kill tumour cells through a dual mechanism of action; the direct lysis of cells, and the induction of an immune response. The first oncolytic virus has been approved in China, and another has been recommended for approval in the United States. This Review discusses the biology of oncolytic viruses as well as key oncolytic viruses in clinical development, and investigates the challenges associated with developing oncolytic viruses as a new therapeutic modality for cancer.
